HBV Forum 5

Print

HBV Forum 5 was held in Vienna, Austria at the Messe Wien Exhibition Congress Center on April 10th, 2019.

 

pdf Agenda

pdf Participants

 

Presentations

pdf Welcoming Remarks

Ryan Anderson, The Forum for Collaborative Research

pdf HDV Therapy—Relevant Recent Findings and Suggested Endpoints

Jeffrey Glenn, Stanford University Medical Center

pdf Molecular Insights into the Synergism Between the HBV/HDV Entry Inhibitor Myrcludex B and Interferon

Stephan Urban, University Hospital Heidelberg

pdf Clinical Challenges in the Development of HDV Infection

Heiner Wedemeyer, Essen University Hospital

pdf Association Between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-analysis

Ryan Anderson, The Forum for Collaborative Research

pdf HBV Forum Immune Monitoring Working Group (IMWG)

Sara Ferrando-Martinez, AstraZeneca

pdf Early Learnings from NUC Stop Studies

Bruce Given, Arrowhead Pharmaceuticals

pdf Stopping NA Treatment

Harry Janssen, Toronto Centre for Liver Disease, University Health Network